These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1469 related items for PubMed ID: 17660867

  • 1. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB.
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [Abstract] [Full Text] [Related]

  • 5. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4116-24. PubMed ID: 14519634
    [Abstract] [Full Text] [Related]

  • 6. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
    Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg AB, Akkafa F.
    Anticancer Res; 2007 Sep 15; 27(6B):3899-902. PubMed ID: 18225548
    [Abstract] [Full Text] [Related]

  • 7. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P.
    Clin Cancer Res; 2004 Sep 01; 10(17):5880-8. PubMed ID: 15355920
    [Abstract] [Full Text] [Related]

  • 8. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M, Shibasaki S, Nanashima A, Yamaguchi H, Yasutake T, Tagawa Y.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [Abstract] [Full Text] [Related]

  • 9. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K.
    Gan To Kagaku Ryoho; 2006 Aug 01; 33(8):1041-8. PubMed ID: 16912518
    [Abstract] [Full Text] [Related]

  • 10. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y, Takahashi K, Saito T.
    Hepatogastroenterology; 2005 Aug 01; 52(66):1715-21. PubMed ID: 16334763
    [Abstract] [Full Text] [Related]

  • 11. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV.
    Clin Cancer Res; 2000 Apr 01; 6(4):1322-7. PubMed ID: 10778957
    [Abstract] [Full Text] [Related]

  • 12. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R.
    Pharmacogenet Genomics; 2006 Nov 01; 16(11):809-16. PubMed ID: 17047489
    [Abstract] [Full Text] [Related]

  • 13. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E, Cuatrecases M, Martínez-Iniesta M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví DG, Serrano T, de Oca J, Peinado MA, Moreno V, Germà JR, Capellá G, Villanueva A.
    J Clin Oncol; 2006 Apr 01; 24(10):1603-11. PubMed ID: 16575011
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S, Yamasaki H, Kitayama Y, Okada T, Maeda S.
    Oncol Rep; 2003 Apr 01; 10(1):109-13. PubMed ID: 12469154
    [Abstract] [Full Text] [Related]

  • 15. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Häusler P, Becker H, Liersch T.
    J Pathol; 2004 Dec 01; 204(5):562-8. PubMed ID: 15538739
    [Abstract] [Full Text] [Related]

  • 16. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B.
    Ther Drug Monit; 2006 Oct 01; 28(5):678-85. PubMed ID: 17038885
    [Abstract] [Full Text] [Related]

  • 17. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):587-94. PubMed ID: 17520254
    [Abstract] [Full Text] [Related]

  • 18. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    Fernández-Contreras ME, Sánchez-Hernández JJ, González E, Herráez B, Domínguez I, Lozano M, García De Paredes ML, Muñoz A, Gamallo C.
    Int J Oncol; 2009 Jan 01; 34(1):219-29. PubMed ID: 19082493
    [Abstract] [Full Text] [Related]

  • 19. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH.
    Clin Cancer Res; 2001 May 01; 7(5):1149-53. PubMed ID: 11350878
    [Abstract] [Full Text] [Related]

  • 20. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW, Wang GQ, Wan DS, Pan ZZ, Li S, Chen G, Liao H.
    Ai Zheng; 2004 Nov 01; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.